The estimated Net Worth of Capital Management Llcbrook... is at least 12.5 百万$ dollars as of 19 February 2014. Capital Llcbrook owns over 350,000 units of Concert Pharmaceuticals Inc stock worth over 12,536,862$ and over the last 11 years Capital sold CNCE stock worth over 0$.
Capital has made over 1 trades of the Concert Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Capital bought 350,000 units of CNCE stock worth 4,900,000$ on 19 February 2014.
The largest trade Capital's ever made was buying 350,000 units of Concert Pharmaceuticals Inc stock on 19 February 2014 worth over 4,900,000$. On average, Capital trades about 350,000 units every 0 days since 2014. As of 19 February 2014 Capital still owns at least 1,497,833 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Capital Llcbrook stock trades at the bottom of the page.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over 69,766,120$ worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth 25,219,472$ . The most active insiders traders include Plc Gsk、Associates Gp Llcqvt Fund V...、Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of 447,820$. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth 50,380$.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: